{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000247","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.195634+00:00","generated_at":"2026-06-06T23:58:34.835953+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Elutia amends Ligand royalty deal; min annual payment rises to $4.4M, $5M milestone waived","bullets":["Minimum Annual Royalty increased from $2.75M to $4.4M for 2024 and each year thereafter through May 2027.","Quarterly minimum payment raised from ~$0.7M to $1.1M; $3.0M lump-sum paid for 2023 Q1-Q3 (half due Jan 20, 2024, half by Apr 10, 2024).","Ligand waived a $5.0M milestone payment that was due in Q2 2023; royalty rate remains 5% of sales on CanGaroo, ProxiCor, Tyke, VasCure."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000247","json":"https://secwatch.observer/filing/0001558370-24-000247.json","markdown":"https://secwatch.observer/filing/0001558370-24-000247.md","text":"https://secwatch.observer/filing/0001558370-24-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/0001558370-24-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/elut-20240110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:58:34.835953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41be83b9f295790a8ec6c9a03d0c602e345e8735","claim":"ELUTIA INC. amended Amendment No. 1 to Royalty Agreement with Ligand Pharmaceuticals Incorporated (effective 2024-01-10).","evidence_excerpt":"On January 10, 2024, Elutia Inc. (the “Company”), through its subsidiary Elutia Med LLC, a Delaware limited liability company (formerly known as Aziyo Med, LLC) (“Elutia Med”), entered into that certain Amendment No. 1 to Royalty Agreement (the “Amendment”), with Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000155837024000247/0001558370-24-000247-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Ligand Pharmaceuticals Incorporated"},{"label":"Effective","value":"2024-01-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}